UK Community Advisory Board (UK-CAB)

UK-CAB 6 – IAS conference feedback

8 August 2003

Notes for the meeting

Introduction to meeting and speakers
Reading Material
Background information – GSK

08:45 Registration and coffee/tea
09:15 Introduction and welcome to the 6th UK-CAB
09:30 Reports and discussion of new data from IAS HIV conference in Paris -Rosy Weston, HIV Pharmacist, St Marys Hospital Including:

  • Triple nucleoside studies
  • T-20 update
  • FTC – a new once daily nuke
  • New formulations of saquinavir and nelfinavir
  • SIMBA study (reducing mother-to-baby transmission and breast-feeding)
11:00 Break
11:30–13:00 Reports and discussion of new data from:

  • Lipodystrophy Workshop in Paris
  • Resistance Workshop in Mexico – Speaker: tbc
1:00–14:00 Lunch
14:00–14:30 Internal meeting
14:30–16:30 Company meeting: GlaxoSmithKline – Dr Claudio Avila, HIV Medical Advisor

  • ACTG 5095 report (Trial with early termination of Trizivir arm)
  • Interaction between abacavir and tenofovir – GSK study and letter to doctors
  • Fosamprenavir – including interactions in dual-PI combinations
  • Ongoing research with current drugs – side effects and toxicity, lipodystrophy etc,
  • Neuropathy and 3TC and abacavir
  • Pigment/nail changes with AZT
  • Viral fitness and 184V mutation
  • New pipeline drugs
16:30 Meeting close

Report from the meeting

Report from 6th UK CAB meeting

PowerPoint Slides from the meeting [some of these are large files]

Feedback report from IAS meeting by Rosy Weston:

CAB6-IAS_RosyWeston.pdf [1.1MB] (pdf file)
CAB6-IAS_RosyWeston.ppt [4.2MB] (powerpoint file)

Feedback report from Resistance and Lipodystrophy workshops by Simon Collins

CAB6-SimonCollins.pdf [0.5MB] (pdf file)
CAB6-SimonCollins.ppt [1.0MB] (powerpoint file)

Background information – GSK

GlaxoSmithKline (GSK) are one of the largest pharmaceutical companies involved in HIV medications and currently have four licensed HIV drugs:

– abacavir (Ziagen)
– AZT (Retrovir)
– 3TC (lamivudine, Epivir)
– amprenavir (Agenerase) and new formulation FosAmprenavir

They produce two combined versions of some of these drugs:

– Combivir (AZT+3TC)
– Trizivir (AZT+3TC+abacavir)

They are also working on new anti-HIV drugs in their development pipeline.

The history of their involvement in HIV/AIDS started with with development of AZT, the first licensed HIV drug, by the Boroughs Wellcome charitable foundation in the 1980. A merger lead to Glaxo Wellcome and when GW merged with SmithKline Beecham in December 2000 GSK became the world’s second largest drug company with turnover in excess of $22 billion.

Dr Claudio Avila is GSKs HIV Medical Advisor and will be able to answer questions on current and pipeline drugs including side effects and any ongoing research.

An agenda for the meeting is included below but there will be plenty of opportunity to ask other questions not included here and we are looking forward to a good discussion.

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Link to top of page